- Shares of Icosavax (ICVX) have more than doubled out of the gate in the vaccine company's first day of trading on the Nasdaq.
- As of 11:49 AM ET, shares were up 122.6% to $33.39.
- Icosavax priced its upsized IPO of 12.13M shares at $15 per share.
- Icosavax is focused on developing vaccines that use virus-like particles. The company says these particles help produce higher density antigens that can lead to stronger and more durable immune responses.
- Seeking Alpha contributor Donovan Jones of IPO Edge has a neutral rating on shares, noting that the company is in the "very-early, high-risk stage" as it just began phase 1 on its lead candidate, IVX-411, for SARS-CoV-2.